Finance

Lists
NVCR:NASDAQ
Novocure Ltd
$15.35
-1.79%
(-0.28) 1D
$15.35
0.00% (0.00)
After hours
Closed: Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVCR...
Open
$15.26
High
$16.07
Low
$15.10
Mkt. cap
1.79B
Avg. vol.
1.23M
Volume
1.00
52-wk high
$21.36
52-wk low
$9.82
EPS
-$1.31
Beta
1.01
Shares outstanding
116.45M
No. of employees
2K
Open
$15.26
High
$16.07
Low
$15.10
Mkt. cap
1.79B
Avg. vol.
1.23M
Volume
1.00
52-wk high
$21.36
52-wk low
$9.82
EPS
-$1.31
Beta
1.01
Shares outstanding
116.45M
No. of employees
2K
News stories
From web sources and news partners
About Novocure Ltd
CEOAsaf Danziger
Employees1.6K
Founded2000
Headquarters-
SectorMedical device
Websitenovocure.com
Analyst ratings
Based on 4 analysts giving stock ratings to NVCR in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for NVCR in the last 3 months.
Highest
Current $15.35
$52.00 (+238.76%)
Average
$29.50 (+92.18%)
Lowest
$17.00 (+10.75%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Hold
Maintained
$20.00
+30.3%
07/24/2026
Jason Bednar
Piper Sandler
Buy
Maintained
$29.00
+88.9%
07/24/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$52.00
+238.8%
07/24/2026
Jessica Fye
J.P. Morgan
Hold
Maintained
$17.00
+10.7%
07/13/2026
Unknown Analyst
Wedbush
Hold
Maintained
$18.00
+17.3%
06/30/2026
Larry Biegelsen
Wells Fargo
Hold
Reiterated
$17.00
+10.7%
05/04/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$20.00
+30.3%
05/01/2026
Unknown Analyst
Ladenburg Thalmann & Co.
Buy
Maintained
$27.00
+75.9%
02/27/2026
Last report
Jul 23, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.13 / -$0.33
+60.80%beat
Revenue / Est. (USD)
183.58M / 172.44M
+6.46%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
167.20M
174.35M
174.06M
183.58M
Cost of goods sold
44.73M
40.45M
38.93M
41.11M
Cost of revenue
44.73M
40.45M
38.93M
41.11M
Research and development expenses
54.03M
60.90M
58.34M
51.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
104.47M
110.18M
144.21M
101.59M
Operating expense
158.50M
171.09M
202.55M
153.04M
Total operating expenses
203.22M
211.53M
241.48M
194.15M
Operating income
-36.02M
-37.18M
-67.42M
-10.56M
Other non operating income
-
-858.00K
-
-
EBT including unusual items
-30.02M
-40.95M
-69.26M
-12.45M
EBT excluding unusual items
-30.02M
-64.64M
-69.26M
-12.45M
Income tax expense
7.25M
-16.46M
1.88M
3.21M
Effective tax rate
-24.14%
40.18%
-2.71%
-25.75%
Other operating expenses
-
-
-
-
Net income
-37.27M
-24.50M
-71.14M
-15.66M
Net profit margin
-22.29%
-14.05%
-40.87%
-8.53%
Earnings per share
-0.33
-0.22
-0.62
-0.13
Interest and investment income
9.80M
-
3.53M
3.57M
Interest expense
-3.80M
-22.27M
-5.37M
-5.46M
Net interest expenses
6.00M
-22.27M
-1.84M
-1.89M
Depreciation and amortization charges
-
-
-
-
EBITDA
-32.36M
-34.48M
-63.30M
-6.26M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps